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oxidation of trimethylamine (TMA) to trimethylamine- N -
oxide (TMAO) ( 1 ). TMA is a gas that has a characteristic 
“fi shy” odor that is produced entirely from the catabolism 
of dietary choline or carnitine by gut microbiota and then 
absorbed into the circulation ( 2, 3 ). Rare loss-of-function 
mutations of FMO3 have been shown to be a cause of “fi sh 
malodor syndrome” or trimethylaminuria, characterized 
by high levels of TMA ( 4–6 ). The incidence of trimethyl-
aminuria caused by  FMO3 mutations in Caucasian popula-
tions is estimated to be 1 in 10,000 ( 4 ). Some but not all 
trimethylaminuria patients have hypertension ( 6 ). How-
ever, common polymorphisms of the  FMO3 gene are not 
associated with hypertension in the Caucasian population 
( 7 ). To the best of our knowledge, whether loss-of-function 
 FMO3 gene mutations infl uence metabolic traits such as 
plasma lipid, glucose, or insulin levels has not been re-
ported. Recently, TMAO was shown to be signifi cantly 
associated with coronary artery disease (CAD) in a large 
cohort of human subjects ( 3 ). A follow-up study confi rmed 
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 Animals, diets, and study design 
 All animal experiments were approved by the University of 
California Los Angeles (UCLA) Animal Care and Use Committee, 
in accordance with Public Health Service guidelines. Eight-week-
old female LDLRKO mice on a C57BL/6J background were 
purchased from the Jackson Laboratory. Beginning at 9 weeks 
of age, they were treated with a control ASO (ISIS 141923, 
5 ′ -CCTTCCCTGAAGG TTCCTCC-3 ′ , 75 mg/kg body weight per 
week) or an FMO3-specifi c ASO (ISIS 555847, 5 ′ -TGGAAGCATTT-
GCCTTTAAA-3 ′ , 50 mg/kg body weight per week) through 
weekly intraperitoneal injection for a total of 13 injections. The 
mice were switched to a Western diet (Harlan TD.88137) during 
the last 8 weeks of the saline/ASO treatment to induce hyper-
lipidemia, a prerequisite for the development of signifi cant ath-
erosclerosis. At the end of the treatment period, the mice were 
fasted for 4 h before blood and tissues were collected for fur-
ther analysis. For FMO3 ASO studies in C57BL/6J mice, 8-week-
old female mice purchased from the Jackson Laboratory were 
treated with control ASO (ISIS 141923, 50 mg/kg body weight 
per week) or FMO3 ASO (ISIS 555847, 50 mg/kg body weight 
per week) through weekly intraperitoneal injection for a total 
of 13 (VLDL secretion study) or 5 (liver free fatty acid level de-
termination study) injections, respectively. Five days after the 
last ASO injection, the mice were examined for VLDL-TG secre-
tion rates or liver free fatty acid determination as described 
subsequently. 
 E3L Tg mice on a C57BL/6J background were a generous gift 
of Dr. L. Havekes (Leiden University Medical Center). FMO3 Tg 
mice ( 1 ) were crossed with the E3L Tg mice ( 11 ) to generate 
FMO3 Tg/E3L Tg and E3L Tg mice for the study. Because the 
ratio of human FMO3 mRNA level to mouse FMO3 mRNA level 
was much greater in male than female FMO3 Tg mice (data not 
shown), we chose to study the male FMO3 Tg mice so that the 
difference in FMO3 expression is greater between the Tg and 
non-Tg mice. Four-month-old male FMO3 Tg/E3L Tg and E3L 
Tg mice fed a low-fat chow diet were fasted for 4 h before collec-
tion of blood for plasma lipid analysis. The mice were then fed a 
high-fat (16% fat)/high-cholesterol (1% cholesterol) (HF/HC) 
diet (D10042101; Research Diets, New Brunswick, NJ) for 16 
weeks and fasted for 16 h before blood and tissues were collected 
for further analysis. 
 Lipid, glucose, and bile acid analyses and liver toxicity 
markers 
 For plasma lipid, lipoprotein, and glucose level determina-
tions, mice were fasted for 4 or 16 h before bleeding. Total cho-
lesterol (TC), HDL cholesterol, unesterifi ed/free cholesterol, 
TGs, free fatty acid, and glucose levels were determined by enzy-
matic colorimetric assays ( 13 ). Phosphatidylcholine levels were 
assayed using an enzymatic colorimetric assay from WAKO (Rich-
mond, VA). Plasma alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) levels were determined using a 
clinical analyzer with reagents purchased from Beckman Coulter 
(Brea, CA). Total bile acids levels were assayed using a kit from 
Diazyme Laboratories (Poway, CA) according to the manufac-
turer’s protocol. For lipid extraction, 50 mg of liver were homog-
enized in PBS, and the lipids then extracted using the Folch 
method ( 14 ). The extracted lipids were dried and resuspended 
in 1% Triton X-100 before lipid assays were performed as de-
scribed previously. Plasma samples were fractionated by fast-protein 
liquid chromatography (FPLC) as described ( 15 ). Plasma con-
centrations of glucagon, interleukin (IL) 6, and insulin were de-
termined by ELISA using kits from R and D systems (Minneapolis, 
MN), eBioscience (San Diego, CA), and ALPCO (Salem, NH), 
respectively. 
those original fi ndings, showing that increased TMAO lev-
els are associated with major adverse cardiovascular events, 
with a hazard ratio for the highest versus lowest quartile of 
2.54 ( 8 ). The increased risk of CAD remained after adjust-
ment for traditional risk factors. Furthermore, TMAO 
appears to be causal for the disease because in mice TMAO 
supplementation of the diet promoted atherosclerosis and 
antibiotic treatment, resulting in a block in TMA produc-
tion, reduced atherosclerosis ( 2, 3 ). The mechanism by 
which TMAO contributes to disease is unknown, but some 
evidence points to altered cholesterol metabolism by mac-
rophages ( 3 ) and diminished reverse cholesterol transport 
( 2 ). Supporting the human results are genetic studies in 
natural variations of TMA and TMAO metabolism in popu-
lations of mice. Thus, in genetic crosses ( 3 ) or in surveys of 
inbred strains ( 1 ) of mice on hyperlipidemic backgrounds, 
TMAO levels were positively associated with atherosclerosis. 
A fraction of this variation was explained by genetic dif-
ferences in FMO3 expression ( 1 ) and variations in gut 
microbiota composition also appear to contribute ( 9 ) (un-
published observations). These results raise the possibility 
that inhibition of FMO3 would lead to reduced levels of 
TMAO and retard the development of atherosclerosis. 
 We had previously shown in mice that second-generation 
antisense oligonucleotide (ASO)-mediated knockdown of 
hepatic FMO3 decreased TMAO levels and that overexpres-
sion of FMO3 using adenoviral transduction or transgenic 
(Tg) mice increased TMAO levels ( 1 ). In order to further 
examine how alterations in FMO3 contribute to atheroscle-
rosis, we now report studies with mouse models of athero-
sclerosis, including the LDL receptor knockout (LDLRKO) 
mouse ( 10 ) and the Apo-E Leiden (E3L) Tg mice, another 
mouse model of hyperlipidemia ( 11 ). Our results confi rm 
that knockdown of FMO3 decreased TMAO levels and ath-
erosclerosis, but they also reveal unexpected effects on glu-
cose and lipid metabolism. Our fi ndings suggest that either 
FMO3 or TMA/TMAO has novel effects on metabolic func-
tions. We show that FMO3 defi ciency leads to decreased 
glucose and lipid levels in the circulation and in the liver, 
whereas FMO3 overexpression has opposite effects, indicat-
ing a role of FMO3 in modulating glucose and lipid homeo-
stasis in vivo. Global gene expression and hepatic metabolite 
analyses suggest that these effects of FMO3 on glucose and 
lipid metabolism may be mediated through the PPAR  and 
Kruppel-like factor 15 (KLF15) pathways. Furthermore, 
studies in a hepatoma cell line in tissue culture suggest that 
the metabolic effects are mediated directly by FMO3 ex-
pression rather than by TMA/TMAO. 
 MATERIALS AND METHODS 
 ASO synthesis 
 A series of uniform chimeric 20-mer phosphorothioate oligo-
nucleotides containing 2’- O -methoxyethyl groups at positions 
1–5 and 15–20 targeted to murine FMO3, as well as a control 
ASO, were synthesized and purifi ed on an automated DNA 
synthesizer using phosphoramidite chemistry as previously de-
scribed ( 12 ). 
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 VLDL-TG secretion assay 
 After 16 h fasting, plasma samples were collected from mice at 
baseline (time 0). The mice were then injected with poloxamer 
407 (Sigma) intraperitoneally at a dose of 1 g/kg body weight. 
After 2 h, plasma samples were collected, and the mice were eu-
thanized for tissue collection. Plasma TG levels at times 0 and 2 h 
were determined as described previously. The rate of VLDL-TG 
secretion was then calculated as described ( 18 ). 
 In vitro studies: adenovirus transduction, glucose 
secretion, and lipogenesis 
 Hep3B cells were cultured in MEM (Life Technologies, Carls-
bad, CA) supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 1 mM sodium pyruvate. 
For the determination of glucose production, Hep3B cells were 
plated in a 6-well plate, at a density of 5 × 10 5 cells/well. They were 
then infected with adenoviruses encoding mouse FMO3 (Ad-
FMO3) or an empty vector (Ad-CMV) at multiplicity of infection 
(MOI) of 50 and cultured for 2 days. Afterwards, the cells were 
washed twice with PBS, then incubated with a glucose production 
media containing DMEM (no glucose), 4 mM  L -glutamine, 20 mM 
sodium lactate, 2 mM sodium pyruvate, 100 U/ml penicillin, and 
100 µg/ml streptomycin for 20 h before the conditioned media 
were collected for determination of glucose concentration by a 
PicoProbe™ Glucose Fluorometric Assay kit (BioVision, Milpitas, 
CA) according to the manufacturer’s protocol. For the lipogenesis 
study, Hep3B cells were plated in a 24-well plate, at a density of 2 × 
10 5 cells/well and then infected with Ad-FMO3 or Ad-CMV at MOI 
of 50 and cultured for 2 days. Afterward, the cells were washed twice 
with PBS and incubated in 0.5 ml of growth media containing 2   Ci 
of  14 C-acetate (50 mCi/mmol; American Radiolabeled Chemicals, 
St. Louis, MO) per well for 3 h before conditioned media, and cell 
lysate was collected for lipid extraction by the Folch method ( 14 ). 
The extracted lipids were spiked with unlabeled lipids (62.5   g 
each of phospholipid, cholesterol, free fatty acid, TG, and choles-
teryl ester), spotted on TLC plates (Silica Gel G plate, Alltech), and 
developed by petroleum ether-ethyl ether-acetic acid (84:15:1). Af-
terward, the lipid bands were stained with 2,7-dichlorofl ourescin 
(Sigma) and visualized using a UV lamp. The  14 C radioactivity as-
sociated with various lipid bands were scraped and counted by 
liquid scintillation counting ( 19 ). The lipid-associated radioactiv-
ity in cell lysate and conditioned media samples was normalized by 
the protein concentration of the cell lysate before comparison. 
 RNA isolation and quantitative RT-PCR analyses 
 Total RNA samples from tissues were isolated using Trizol re-
agent (Life Technologies) according to the manufacturer’s pro-
tocol. The cDNA was synthesized using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Quantitative 
PCR was performed using gene-specifi c primers (supplementary 
Table 1) and the Roche SYBR green master mix in a Roche Light-
cycler 480 system (Roche). The mRNA levels of specifi c genes 
were normalized to the mRNA levels of the housekeeping gene, 
Rpl13a, of the same sample. 
 Expression microarray 
 Total RNA samples from the livers of LDLRKO mice treated 
with control or FMO3 ASO (n = 4 for each group) were prepared 
for use in Illumina MouseRef-8 v2.0 Expression BeadChips ac-
cording to manufacturer’s recommendations at the Neurosci-
ence Genomics Core at UCLA. Array data were processed using 
the limma R package; any probes that were not expressed (detec-
tion  P value <0.05) in any of the arrays were excluded. Differen-
tial expression ratios were then calculated for the two groups 
(Control ASO vs. FMO3 ASO) and fi ltered at a 5% false discovery 
 Quantifi cation of TMA, TMAO, bile acids, and free fatty 
acids by mass spectrometry 
 Quantifi cation of TMAO and TMA in plasma samples was per-
formed using stable isotope dilution HPLC with on-line electro-
spray ionization tandem mass spectrometry on an API 365 triple 
quadrupole mass spectrometer (Applied Biosystems, Foster, CA) 
interfaced with a Cohesive HPLC (Franklin, MA) equipped with 
phenyl column (4.6 × 2,505 mm, 5   m Rexchrom Phenyl; Regis, 
Morton Grove, IL), and the separation was performed as re-
ported previously ( 3 ). 
 Bile acid was extracted from small intestine and liver/gallbladder 
with ethanol as described by Argmann et al. ( 16 ). Bile acid internal 
standard mixture containing deoxycholic-2,2,4,4-d4 acid (C/D/N 
Isotopes cat. no. D-2941); cholic-2,2,4,4-d4 acid (C/D/N Isotopes 
cat. no. D-2452); glycochenodeoxycholic-2,2,4,4-d4 acid (C/D/N 
Isotopes cat. no. D-5673); and glycocholic-2,2,4,4-d4 acid (C/D/N 
Isotopes cat. no. D-3878) was added to the ethanolic extract at a fi nal 
concentration of 10   M each. Supernatants (20   l) were analyzed 
by injection onto a Prodigy 5 u ODS ( 2 ) column (2.0 × 150 mm, 
5 µm Luna silica, cat. no. 00F-3300-B0; Phenomenex, Torrance, CA) 
at a fl ow rate of 0.2 ml min   1 . Separation was performed using a 
discontinuous gradient generated by mixing solvent A (0.2% formic 
acid in water) with solvent B (0.2% formic acid in acetonitrile) at 
different ratios starting from 25% B for 5 min, then linearly to 100% 
B over 15 min, followed by 100% B for 5 min and then back to 25% 
B over 1 min. The HPLC column effl uent was introduced into an 
API 365 triple quadrupole mass spectrometer with Ionics EP 10+ 
upgrade (Concord, Ontario, CA) interfaced to a Cohesive Tech-
nologies Aria LX Series HPLC multiplexing system. Analyses were 
performed using electrospray ionization in negative-ion mode with 
multiple reaction monitoring of parent and characteristic daughter 
ions specifi c for components monitored. The transitions monitored 
were  m/z :  m/z 391 → 345 for deoxycholic acid;  m/z 395 → 349 for 
deoxycholic-2,2,4,4-d4 acid;  m/z 407 → 371 for   -muricholic acid and 
  -muricholic acid;  m/z 407 → 343 for cholic acid;  m/z 411 → 347 
for cholic-2,2,4,4-d4 acid;  m/z 432 → 74 for glycolithocholic acid; 
 m/z 448 → 74 for glycochenodeoxycholic acid, glycodeoxycholic 
acid, glycohyodeoxycholic acid, and glycoursodeoxycholic acid;  m/z 
452 → 74 for glycochenodeoxycholic-2,2,4,4-d4 acid;  m/z 464 → 74 
for glycocholic acid;  m/z 468 → 74 for glycocholic-2,2,4,4-d4 acid;  m/z 
482 → 124 for taurolithocholic acid;  m/z 498 → 124 for taurochenode-
oxycholic acid, taurodeoxycholic acid, taurohyodeoxycholic acid, 
and tauroursodeoxycholic acid; and  m/z 514 → 124 for tauro-  -
muricholic acid, tauro-  -muricholic acid, and taurocholic acid. Vari-
ous concentrations of nonisotopically labeled bile acid standard mix 
were spiked into internal standard mix to prepare the calibration 
curves for quantifi cation of individual bile acids. Deoxycholic-
2,2,4,4-d4 acid was used as internal standard for deoxycholic acid; 
cholic-2,2,4,4-d4 acid for   -muricholic acid,   -muricholic acid, and 
cholic acid; glycochenodeoxycholic-2,2,4,4-d4 acid for glycocheno-
deoxycholic acid, glycodeoxycholic acid, glycohyodeoxycholic acid, 
and glycoursodeoxycholic acid; and glycocholic-2,2,4,4-d4 acid for 
all the other bile acid species. 
 Liver free fatty acids levels were quantifi ed using mass spec-
trometry as previously described ( 17 ). 
 Quantifi cation of enzymatic activity of FMOs in the liver 
 Quantifi cation of enzymatic activity of hepatic FMOs was con-
ducted in 250   l reaction mix containing 1 mg liver protein ho-
mogenate, 100   M d9-TMA, and 100   M NADPH in 10 mM 
HEPES, pH 7.4. The reaction was stopped after 8 h with 0.2 N 
formic acid followed by fi ltering through a 3 K cutoff spin fi lter. 
The fi ltrate was injected onto an HPLC column with on-line tan-
dem mass spectrometer to measure the oxidized product d9-
TMAO ( 3 ). 
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 FMO3 knockdown results in altered levels of 
plasma lipoproteins and insulin in LDLRKO mice 
fed a Western diet 
 Mice injected with the FMO3 ASO exhibited dramati-
cally decreased levels of plasma lipids, including TG, HDL, 
VLDL/IDL/LDL, unesterifi ed cholesterol, and free fatty 
acids, as compared with mice treated with the control ASO 
( Table 1 ).  The control ASO had a slight effect on plasma 
TG levels and HDL cholesterol levels but did not affect the 
other lipids ( Table 1 ). These results were consistent with 
FPLC analyses, which revealed decreased levels of TG, TC, 
and phosphatidylcholine in the VLDL and IDL/LDL frac-
tions of the FMO3 ASO plasma samples as compared with 
those of the control ASO samples ( Fig. 3A–C ).  Decreased 
levels of TC and phosphatidylcholine were also observed 
in the HDL fractions of the FMO3 ASO plasma samples 
( Fig. 3B, C ). Bile acids were elevated about 2-fold in the 
FMO3 ASO-injected mice ( Fig. 4C ).  In addition to these 
rate cutoff. Fisher’s exact test was performed to determine whether 
there is an enrichment of PPAR  target genes ( 20, 21 ) in the dif-
ferentially expressed (DE) gene set. 
 Atherosclerosis lesion analyses 
 Atherosclerotic lesion size at the aortic root and proximal aorta 
was determined as described ( 13 ). Immunohistochemistry was 
performed, as previously described ( 22 ), using primary antibodies 
against cluster of differentiation 68 (CD68) (AbD Serotec, Raleigh, 
NC) to determine macrophage content of the aortic root lesion. 
 Statistical analyses 
 Student’s  t -test was utilized for comparison of means between 
two groups. In addition, ANOVA was used to compare means 
among three treatment groups. Values shown in bar graphs and 
tables are means and standard errors of the treatment groups. 
Biweight midcorrelation analysis was performed to examine the 
pair-wise relationships between plasma TMAO, HDL-cholesterol, 
VLDL/IDL/LDL-cholesterol levels, and atherosclerotic lesion 
size among 133 female mice that were bred onto a hyperlipid-
emic apoB Tg mouse background (apoB Tg/HMDP) ( 1, 23 ). 
Stepwise linear regression analysis was performed to examine the 
relative importance of TMAO, HDL-cholesterol, and VLDL/
IDL/LDL-cholesterol in infl uencing atherosclerotic lesion size 
among 133 female apoB Tg/HMDP mice ( 1, 23 ). 
 RESULTS 
 FMO3 knockdown in vivo in LDLRKO mice: effects on 
TMA/TMAO and atherosclerosis 
 To examine how FMO3 expression infl uences athero-
genesis, we administered saline, a control ASO, or an 
FMO3 ASO to LDLRKO mice for 13 weeks. During the last 
8 weeks of the ASO treatment, the mice received a West-
ern diet to enhance plasma cholesterol levels and athero-
sclerosis development. At the end of the study, the mice 
were euthanized and examined for plasma TMA/TMAO 
levels and atherosclerosis. We observed >90% reduction in 
FMO3 protein expression in the livers of the FMO3 ASO-
treated mice as compared with the saline- and control 
ASO-treated mice ( Fig. 1A ).  Liver FMO activity as mea-
sured by conversion of TMA to TMAO was decreased by 
87% in the liver samples of FMO3 ASO-treated mice as 
compared with those of the control ASO group ( Fig. 1B ). 
Circulating TMAO levels in the FMO3 ASO-treated mice 
were decreased by about 50% as compared with the con-
trol ASO-treated mice ( Fig. 1C ), whereas circulating TMA 
levels were signifi cantly increased in the FMO3 ASO-treated 
mice ( Fig. 1D ). While the FMO3 ASO treatment did not 
discernibly affect body weight as compared with the control 
groups ( Fig. 1E ), it did result in a small but signifi cant re-
duction in weight of four major fat pads ( Fig. 1F ). 
 We observed a signifi cant decrease in atherosclerotic le-
sion size at the aortic root of the FMO3 ASO group as com-
pared with both the saline and the control ASO groups 
( Fig. 2A ), whereas no difference in atherosclerotic lesion 
size was observed between the saline and control ASO 
groups ( Fig. 2A ).  The macrophage content of lesions, as 
assessed by the relative area of CD68 staining, was similar 
(  70%) in all three groups ( Fig. 2B ). 
 Fig.  1. FMO3 knockdown in LDLRKO mice leads to decreased 
hepatic FMO3 protein and activity levels, altered plasma TMAO 
and TMA levels, and decreased adiposity. A: Liver FMO3 protein 
levels of mice treated with saline (S), control ASO (control), or 
FMO3 ASO (FMO3) were determined by immunoblotting. B: Liver 
FMO activity (n = 6 for each group) was determined using TMA as 
the substrate. Plasma TMAO (C) and TMA (D) levels were deter-
mined by mass spectrometry (n = 12 for each group). Body weight 
(E) and percent weight of four fat pads (gonadal, retroperitoneal, 
subcutaneous, and mesentery fat pads) (F) were normalized by the 
body weight (n = 12 for each group). Student’s  t -test:  #  P < 0.05 as 
compared with the saline group; *  P < 0.05 as compared with 
the control ASO group. ANOVA:  &  P < 0.05 between the means of 
the three treatment groups. 
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effects, the FMO3 ASO-treated mice also exhibited signifi -
cant decreases in both glucose and insulin levels as com-
pared with the control ASO treated mice ( Table 1 ). 
 To evaluate the potential toxic effects of FMO3 ASO 
treatment, we measured plasma ALT and AST levels as bio-
markers for normal liver function. Although levels were 
elevated about 2-fold in the FMO3 ASO-treated mice as 
compared with the control ASO-treated mice ( Fig. 4A, B ), 
they did not exceed the normal ranges previously reported 
for untreated LDLRKO ( 15 ) and C57BL/6 mice ( 24 ). Fur-
ther, circulating levels of a proinfl ammatory cytokine, IL-6, 
were similar between the FMO3 ASO-treated mice and the 
saline- and control ASO-treated mice ( Fig. 4E ). Circulat-
ing levels of urea, a metabolite mainly produced by the 
liver, were signifi cantly decreased in the FMO3 ASO-
injected mice as compared with the saline- and control 
ASO-treated mice ( Fig. 4D ). Thus, FMO3 knockdown in 
 Fig.  2. FMO3 knockdown in LDLRKO mice leads to decreased 
atherosclerotic lesion development. A: Atherosclerotic lesion size 
at the aortic root region of mice treated with saline, control ASO, 
or FMO3 ASO and fed the Western diet are shown. N = 11 for each 
group. Symbols are the same as  Fig. 1 . B: Macrophage content in 
the atherosclerotic lesions of the aortic root region was determined 
by immunohistochemistry using antibodies against CD68. Four 
mice from each group with three lesion sections per mouse were 
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 Fig.  3. Altered plasma lipoprotein profi le in FMO3 ASO-treated 
LDLRKO mice fed a Western diet. FPLC was used to fractionate 
pooled plasma samples (fi ve individual samples per pool) from LD-
LRKO mice treated with the control ASO or the FMO3 ASO and 
fed the Western diet. TG (A), TC (B), and phosphatidylcholine 
(C) concentrations of each FPLC fraction were measured and shown. 
 Fig.  4. FMO3 knockdown in LDLRKO mice is associated with in-
creased levels of hepatotoxicity markers and bile acids and de-
creased levels of urea in the blood. Plasma ALT (A), plasma AST 
(B), plasma total bile acid (C), plasma urea (D), and plasma IL-6 
(E) concentrations are shown. For A–E, n = 10 to 12 per group. 
Symbols are the same as in  Fig. 1 . 
mice is associated with changes in the levels of plasma lipo-
proteins, glucose, and insulin, without signifi cant impair-
ment in liver function. 
 FMO3 knockdown alters hepatic lipid and 
glucose metabolism 
 We observed signifi cantly decreased levels of TGs, TC, and 
phosphatidylcholine in the livers of FMO3 ASO-injected 
mice as compared with those of the saline- and control 
ASO-treated mice ( Fig. 5A–C ), whereas control ASO-
injected mice were unaffected in hepatic lipids except for 
a small decrease in liver TG content as compared with the 
saline group ( Fig. 5A ).  Liver glucose levels in the FMO3 
ASO-injected mice were signifi cantly lower as compared 
with the control ASO group ( Fig. 5D ), while liver glycogen 
levels of the FMO3 ASO and control ASO groups were 
both slightly elevated as compared with the saline group 
( Fig. 5E ). 
 To examine the effects of the ASO on hepatic gene ex-
pression, we performed quantitative RT-PCR. We observed 
signifi cantly decreased expression of several genes in-
volved in lipogenesis, including sterol-regulatory element 
binding protein 1c ( Srebp-1c ), fatty acid synthase ( Fasn ), 
malic enzyme ( Me ), stearoyl-CoA desaturase-1 ( Scd-1 ), and 
ELOVL family member 6, elongation of long chain fatty 
acids ( Elovl6 ) in the livers of FMO3 ASO-treated mice as 
compared with those of the control ASO group ( Fig. 5F ). 
These data provided a potential mechanism for reduced 
hepatic TG and phosphatidylcholine levels found in the 
FMO3 ASO-treated group as compared with the control 
ASO-treated group. The mRNA level for microsomal TG 
transfer protein ( Mttp ) was signifi cantly decreased in the 
FMO3 ASO-treated group as well ( Fig. 5F ), providing an 
explanation for decreased VLDL levels seen in these mice 
( Fig. 3 ). Signifi cant decreases in the expression of genes 
involved in gluconeogenesis or its regulation, such as  Alt , 
fi broblast growth factor 21 ( Fgf21 ), peroxisome prolifera-
tor activated receptor   coactivator protein-1  (Pgc-1  ), 
forkhead box O1 ( Foxo1 ), glucose-6-phosphatase, catalytic 
subunit ( G6pc ), pyruvate dehydrogenase kinase, isozyme 4 
( Pdk4 ), and phosphoenolpyruvate carboxykinase ( Pepck ) 
were also observed in FMO3 ASO group as compared with 
the control ASO group ( Fig. 5F ). These transcriptional 
changes may explain, in part, the decreased plasma and 
hepatic glucose levels observed in the FMO3 ASO-treated 
group. The mRNA levels of genes involved in fatty acid 
oxidation, such as acyl-CoA dehydrogenase, long-chain 
( Acadl ) and enoyl-CoA, hydratase/3-hydroxyacyl CoA de-
hydrogenase ( Ehhadh ) were also signifi cantly decreased in 
the FMO3 ASO-treated group ( Fig. 5F ). 
 PPAR  and KLF15 pathways perturbed by 
FMO3 knockdown 
 Because substantial decreases in mRNA levels of many 
genes involved in glucose and lipid metabolism were 
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between the control ASO- and FMO3 ASO-treated groups. 
Overall, 27% of the liver transcripts (4,223 out of 15,552) 
were DE between the two groups with about 50% of the 
DE transcripts upregulated and the other 50% downregu-
lated. In contrast, out of 331 PPAR  target genes, 156 of 
those (47%, 136 downregulated and 20 upregulated) were 
DE between FMO3 ASO- and control ASO-treated groups 
(supplementary Table 2). Thus, we observed an enrich-
ment of PPAR  target genes in the DE gene set (Fisher’s 
observed in the FMO3 ASO-treated group, we asked 
whether the expression levels of transcription factors regu-
lating these processes, including liver X receptor (LXR)   , 
LXR  , and PPAR  , were altered in these mice. Our data 
showed that the expression of LXR  and LXR  was not 
changed in the FMO3 ASO-treated group, whereas PPAR  
mRNA levels were signifi cantly decreased in the FMO3 
ASO-treated group ( Fig. 5F ). Global gene expression pro-
fi ling analysis was performed to identify DE liver genes 
 Fig.  5. FMO3 knockdown in LDLRKO mice leads to altered hepatic glucose and lipid levels, altered hepatic gene 
expression, and changes in plasma metabolites. Liver TG (A), TC (B), phosphatidylcholine (C), glucose (D), and 
glycogen (E) levels were determined in LDLRKO mice treated with saline, control ASO, or FMO3 ASO and fed the 
Western diet (n = 8 for each group). F: Liver mRNA levels (n = 6 for each group) of genes involved in lipid and 
glucose metabolism were quantifi ed by quantitative PCR and normalized by the mRNA level of the housekeeping 
gene,  Rpl13a . In a separate set of mice, circulating levels of amino acids (G), glucose (H),   -hydroxybutyrate (I), and 
glucagon (J) were determined (n = 10 for each group). Symbols are the same as in  Fig. 1 . 
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 FMO3 knockdown alters bile acid metabolism, fecal lipid 
content, and intestinal gene expression 
 Because the substrate for FMO3, TMA, is produced by 
gut microbiota, we asked whether the lower plasma and 
hepatic lipid levels might be mediated by bile acid metabo-
lism, intestinal cholesterol absorption, or TG digestion. 
Bile samples collected from the gall bladders of FMO3 
ASO-treated mice exhibited signifi cantly lower levels of 
cholesterol, bile acids, and phosphatidylcholine as com-
pared with those of the saline- and control ASO-treated 
mice ( Fig. 6A ).  FMO3 ASO-treated mice exhibited signifi -
cantly decreased bile acid pool size as compared with the 
control ASO group ( Fig. 6B , left panel). The levels of vari-
ous bile acids, including cholate, taurocholate, tauroche-
nodeoxycholate, tauro-  -muricholate, taurodeoxycholate, 
and tauroursodeoxycholate, were signifi cantly decreased 
by >50% in the liver/gallbladder of FMO3 ASO-treated 
mice ( Fig. 6B , middle panel). The levels of taurochenode-
oxycholate, tauro-  -muricholate, taurodeoxycholate, and 
tauroursodeoxycholate were signifi cantly decreased in the 
small intestine of the FMO3 ASO-treated mice as well ( Fig. 
6B , right panel). Interestingly, two major bile acids, tauro-
cholic acid and tauro-  -muricholic acid, were increased in 
both the control ASO and FMO3 ASO groups as compared 
with the saline group in the small intestine ( Fig. 6B , right 
panel). This might be caused by a nonspecifi c effect of the 
ASO in general. Hepatic mRNA levels of enzymes involved 
in bile acid synthesis [including cytochrome P450, fam-
ily 7, subfamily A, polypeptide 1 ( Cyp7a1 ); cytochrome 
P450, family 8, subfamily b, polypeptide 1 ( Cyp8b1 ); and 
cytochrome P450, family 27, subfamily A, polypeptide 1 
( Cyp27a1 )] were all signifi cantly reduced in the FMO3 
ASO-treated mice ( Fig. 6C ), suggesting that lower hepatic 
bile acid synthesis may account for the lower bile acid con-
centrations found in the bile, liver, and small intestine of 
these mice. Hepatic mRNA levels of the bile acid trans-
porter, Na/taurocholate cotransporting polypeptide 1 
( Ntcp ), were also lower in the FMO3 ASO-treated mice 
( Fig. 6C ). This might also explain the higher circulating 
bile acid levels observed in these mice. We also observed 
increased infl ammation in the livers of FMO3 ASO-treated 
mice as evidenced by increased mRNA levels for  Cd68 , a 
marker for macrophages, and tumor necrosis factor   
( Tnf  ) ( Fig. 6C ). The cholesterol content of the fecal sam-
ples collected from the FMO3 ASO-treated mice were sig-
nifi cantly higher as compared with those of saline- and 
control ASO-treated mice ( Fig. 6D ), indicating either 
lower intestinal cholesterol absorption or increased cho-
lesterol excretion in the FMO3 ASO-treated mice. Fecal 
TG contents, on the other hand, were not affected by the 
FMO3 ASO treatment ( Fig. 6D ). We further examined 
gene expression in the small intestine of these mice. Inter-
estingly, the mRNA levels of Niemann-Pick C1-like 1 
( Npc1l1 ), a key player in intestinal cholesterol absorption, 
were signifi cantly lower in the FMO3 ASO-treated mice 
( Fig. 6E ), which may explain, in part, the increased fecal 
cholesterol levels seen in the FMO3 ASO-treated mice. 
The mRNA levels of the cholesterol transporters,  Abcg5 and 
 Abcg8 , were also decreased in the FMO3 ASO-treated mice 
exact test,  P = 3.6 × 10   15 ). Furthermore, 87% (136 out 
of 156) of the DE PPAR  target genes versus 50% of 
transcripts of the overall DE gene set were downregulated in 
the FMO3 ASO groups (Fisher’s exact test,  P = 2.7 × 10   23 ). 
Therefore, our data show that FMO3 knockdown prefer-
entially decreased PPAR  target gene expression in the 
liver. Our results suggest that FMO3 may infl uence lipid 
and glucose metabolism through modulating PPAR  ex-
pression and activity. 
 To further examine why FMO3 knockdown leads to de-
creased levels of circulating and hepatic glucose in LD-
LRKO mice, we examined the circulating levels of 12 
amino acids that are glucogenic and/or ketogenic in a 
second set of mice that received either control or FMO3 
ASO treatment. Interestingly, the levels of 7 out of these 
12 amino acids examined, namely, Glu, Ile, Leu, Pro, Trp, 
Tyr, and Val, were signifi cantly elevated, by 14% to 38%, as 
compared with those of the control ASO-treated mice 
( Fig. 5G ). Plasma glucose and   -hydroxybutyrate (a ke-
tone body produced by the liver) in these FMO3 ASO-
treated mice were also signifi cantly lower as compared 
with the control ASO-treated mice ( Fig. 5H, I ). We noticed 
that plasma glucose levels ( Fig. 5H ) of this second set of 
mice, housed at UCLA, were generally lower than those of 
the fi rst set of mice, housed at ISIS ( Table 1 ), although 
both experiments used similar study protocols [LDLRKO 
females, Western diet, same ASOs, and same duration of 
fasting (4 h)]. However, differences in the environment, 
animal handling, and stress levels of the mice could all 
contribute to the differences in plasma glucose levels ob-
served between these two cohorts of mice. Our data sug-
gest decreased hepatic gluconeogenesis and ketone body 
production in the FMO3 ASO-treated mice as compared 
with the control ASO-treated mice. However, circulating 
glucagon levels were similar between the FMO3 ASO- and 
control ASO-treated mice ( Fig. 5J ), indicating that the de-
creased hepatic expression of gluconeogenic genes in the 
livers of FMO3 ASO-treated mice ( Fig. 5F ) was not due 
to decreased glucagon stimulation. On the other hand, 
Fgf21 and Pgc-1  mRNA levels were signifi cantly de-
creased in the FMO3 ASO-treated group ( Fig. 5F ). FGF21 
is a PPAR  target gene that induces PGC-1  expression, 
leading to increased gluconeogenesis and ketogenesis 
( 25 ). Therefore, decreased FGF21 and PGC-1  expres-
sion in the liver may be one of causes leading to decreased 
plasma glucose and ketone levels observed in the FMO3 
ASO-treated mice. 
 The Klf15 is a transcription factor that regulates gluco-
neogenesis, amino acid degradation, and urea cycle in the 
liver ( 26–28 ). Our liver microarray data revealed signifi -
cant decreases in the mRNA levels of  Klf15 and some of its 
target genes including  G6c ,  Pck1 , ornithine transcarba-
mylase ( Otc ),  Prodh , and  Hpd in the FMO3 ASO-treated 
group (supplementary Table 3). The decreased expres-
sion of  Klf15 and its target genes could also explain, at 
least in part, the decreased plasma and liver glucose lev-
els, decreased plasma urea level, and increased plasma 
gluconeogenic amino acid levels seen in the FMO3 ASO-
treated mice. 
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 FMO3 knockdown results in altered plasma lipoprotein, 
glucose, and insulin levels and decreased hepatic VLDL-
TG secretion in nonhyperlipidemic genetic background 
 We examined the effects of FMO3 knockdown in a sepa-
rate cohort of female C57BL/6J (B6) mice injected with ei-
ther control or FMO3 ASO for 13 weeks while maintained 
on a low-fat chow diet. B6 mice injected with the FMO3 
ASO showed signifi cant decreases in plasma TGs, HDL, and 
unesterifi ed cholesterol levels as compared to the control 
ASO-treated mice ( Table 2 ).  The FMO3 ASO-treated mice 
also exhibited signifi cant decreases in both glucose and in-
sulin levels as compared with the control ASO-treated mice 
( Table 2 ). Hepatic TG levels were signifi cantly decreased 
in the FMO3 ASO-treated group ( Fig. 7A ), and this was 
as compared with the saline- and control ASO-treated mice 
( Fig. 6E ). The mRNA levels of two farnesoid X receptor 
(Fxr) target genes, fi broblast growth factor 15 ( Fgf15 ) and 
small heterodimer partner ( Shp ), were also signifi cantly 
decreased in the FMO3 ASO-treated mice ( Fig. 6E ), sug-
gesting decreased intestinal bile acid levels in the FMO3 
ASO-treated mice. The mRNA levels of genes involved in 
bile acid transport, including apical sodium dependent 
bile acid transporter ( Asbt ), intestinal bile acid binding 
protein ( Ibabp ), multidrug resistance-associated protein 2 
( Mrp2 ), and organic solute transporter   ( Ost  ), were sim-
ilar between the FMO3 ASO and control ASO groups 
( Fig. 6E ), providing indirect evidence that FMO3 knockdown 
did not directly affect bile acid transport in the intestine. 
 Fig.  6. FMO3 knockdown in LDLRKO mice leads 
to altered bile composition, bile acid pool size, fecal 
lipid output, and intestinal gene expression. Bile 
acid, cholesterol, and phosphatidylcholine (PC) lev-
els of bile collected from the gall bladder (A), bile 
acid (BA) pool size and composition (B) [for bile 
acid composition, only the major (  0.5% of total 
amount) bile acid species are plotted], hepatic 
mRNA levels (C), daily fecal output of cholesterol 
and TG (D), and mRNA levels (E) in the small intes-
tine of LDLRKO mice treated with saline, control 
ASO, or FMO3 ASO were determined (n = 6 for 
each group). Symbols are the same as in  Fig. 1 . CA, 
cholic acid; CDCA, chenodeoxycholic acid; DCA, 
deoxycholic acid; HDCA, hyodeoxycholic acid; MCA, 
muricholic acid; T, taurine conjugated; UDCA, urso-
deoxycholic acid. 
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decreased hepatic expression of PPAR  target genes asso-
ciated with FMO3 knockdown (supplementary Table 2). 
 FMO3 knockdown using a second FMO3 ASO results in 
altered plasma lipoprotein, glucose, and insulin levels 
 To rule out the possibility that the lipid- and glucose-
lowering effect of the FMO3 ASO used in the LDLRKO 
and B6 mouse studies described previously was due to a 
nonspecifi c effect, we examined the effect of a second 
FMO3 ASO (FMO3 ASO#2, ISIS 555926) on plasma lipid 
and glucose levels in B6 mice. After six weekly ASO injec-
tions, male B6 mice treated with the FMO3 ASO#2 showed 
signifi cant decreases in plasma TGs, total, HDL, and un-
esterifi ed cholesterol levels as compared with the control 
ASO-treated mice (supplementary Table 4). The FMO3 
ASO#2-treated mice also exhibited signifi cant decreases in 
both glucose and insulin levels as compared with the con-
trol mice (supplementary Table 4). Thus, FMO3 knock-
down using two independent FMO3 ASOs in vivo yielded 
reproducible lipid- and glucose-lowering effects, indicat-
ing a role for FMO3 in lipid and glucose homeostasis. 
accompanied by a small but signifi cant increase in TC level 
( Fig. 7A ).  No differences in phosphatidylcholine levels were 
observed between the two groups of mice ( Fig. 7A ). FMO3 
ASO-treated mice exhibited a signifi cant 20% decrease in 
TG secretion rate as compared with the control mice ( Fig. 
7B ), suggesting that the decreased plasma TG levels ob-
served in the FMO3 ASO-treated mice ( Table 2 ) were 
caused, in part, by decreased TG secretion from the liver. 
 In a second study, saturated and unsaturated fatty acids 
in the liver samples of female C57BL/6J mice injected 
with either control or FMO3 ASO for 5 weeks were quanti-
fi ed by mass spectrometry. We observed no signifi cant dif-
ferences in most of the saturated fatty acids measured, 
except for decreased caproate and myristate levels in the 
FMO3 ASO group ( Fig. 7C ). In contrast, hepatic levels of 
most of the unsaturated fatty acids, including palmitole-
ate, oleate,   -/  -linolenate, and EPA, were signifi cantly 
decreased in the FMO3 ASO-treated group as compared 
with the control ASO group ( Fig. 7D ). Because many un-
saturated fatty acids are known PPAR  ligands ( 21 ), the 
decreased levels of unsaturated fatty acids observed in 
the livers of FMO3 ASO-treated mice may explain the 
 TABLE 2. Plasma lipid, lipoprotein, glucose, and insulin levels of female B6 mice injected with control or FMO3 ASO and maintained on a 
chow diet 




Cholesterol Free Fatty Acids Glucose Insulin
Control ASO 8 103 (24) 93 (4) 64 (3) 28 (2) 14 (1) 55 (7) 130 (8) 260 (49)
FMO3 ASO 8 50 (11) a 70 (5) a 50 (5) a 21 (2) 11 (1) a 50 (5) 111 (6) a 136 (13) a 
Mice were fasted for 16 h. Values shown are means (standard errors) of the groups. Units are mg/dl except insulin, for which the unit is pg/ml. 
 a P < 0.05 versus control ASO.
 Fig.  7. FMO3 knockdown in C57BL/6J mice fed a 
chow diet leads to decreased liver TG and fatty acid 
concentrations and a decreased rate of secretion of 
VLDL-TG. Female C57BL/6J mice were treated with 
control or FMO3 ASO for 13 weeks before liver con-
centrations of TG, TC, and phosphatidylcholine 
(PC) (A), and the rate of VLDL-TG secretion (B) 
were determined (n = 8 for each group). In a sepa-
rate study, the levels of saturated fatty acids (C) and 
unsaturated fatty acids (D) in the livers of C57BL/6J 
mice treated with fi ve weekly injections of control or 
FMO3 ASO were determined by mass spectrometry 
(n = 4 for each group). Student’s  t -test: *  P < 0.05 as 
compared with the control ASO group. 
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TMA levels were similar between the two groups ( Fig. 8A , 
right panel). We also observed increased TG accumula-
tion in the livers of FMO3 Tg mice ( Fig. 8B ), although 
hepatic TC and phosphatidylcholine levels were similar 
between the two groups ( Fig. 8B ). There was a signifi cant 
10% increase in overall bile acid pool size in the FMO3 
Tg/E3L Tg mice as compared with the E3L Tg mice ( Fig. 
8C , left panel). The hepatic concentrations of various bile 
acids were similar between the FMO3 Tg/E3L Tg and E3L 
Tg mice except for a small but signifi cant decrease in tau-
roursodeoxycholate level in the FMO3 Tg/E3L Tg mice 
( Fig. 8C , middle panel). There were signifi cant increases 
in tauro-chenodeoxycholate (54% increase) and tauro-  -
muricholate (31% increase) levels in the small intestine of 
FMO3 Tg/E3L Tg mice ( Fig. 8C , right panel). Hepatic 
gene expression analysis revealed no signifi cant differ-
ences in mRNA levels of genes involved in lipid, glucose, 
bile acid, or cholesterol metabolism between the FMO3/
E3L Tg and E3L Tg mice (supplementary Fig. 3A). Gene 
expression analysis of the small intestine revealed a signifi -
cant decrease in  Asbt mRNA level in the FMO3 Tg/E3L Tg 
mice (supplementary Fig. 3B), whereas no other changes 
in the expression of genes involved in cholesterol and bile 
acid transport were observed. Asbt is the major bile salt 
uptake protein in the small intestine. FXR is shown to in-
hibit the expression of mouse  Asbt via the FXR-SHP-liver 
receptor homolog -1 cascade ( 29 ). Because the FMO3 Tg/
E3L Tg mice had a signifi cant 54% increase in tauro-
chenodeoxycholate, a potent FXR ligand, in the small in-
testine, this may explain the decreased  Asbt expression in 
these mice. In addition, FMO3 Tg mice exhibited signifi -
cantly increased body weight ( Fig. 8D ) and adiposity ( Fig. 
8E ) after the HF/HC diet feeding. There was a small in-
crease (20%) in atherosclerotic lesion size in the FMO3 
Tg/E3L Tg mice (vs. E3L Tg,  P = 0.23;  Fig. 8F ). Therefore, 
data from the FMO3 Tg mice support a role for FMO3 in 
glucose, lipid homeostasis, and adiposity. 
 Overexpression of FMO3 in Hep3B cells enhances 
lipogenesis and glucose production 
 To further examine the effect of FMO3 on lipid and 
glucose metabolism, we infected the human Hep3B hepa-
toma cells with control (Ad-CMV) or mouse FMO3-encoding 
adenoviral vectors ( 1 ). Forty-eight hours after infection, 
we observed high levels of FMO3 protein being expressed 
in the Ad-FMO3-infected cells as compared with the 
 Overexpression of human FMO3 in Tg mice results in 
altered plasma lipoprotein, glucose, and insulin levels; 
altered hepatic lipid contents; and increased adiposity 
 We examined FMO3 Tg mice to determine whether 
FMO3 overexpression also has an impact on plasma lipids 
and glucose metabolism. We previously reported the gen-
eration of FMO3 Tg mice overexpressing human FMO3 
from a liver-specifi c albumin promoter ( 1 ). The male 
FMO3 Tg mice exhibited a signifi cant 55% increase in 
liver FMO activity (supplementary Fig. 1) and a signifi cant 
75% increase in plasma TMAO levels as compared with 
the male non-Tg littermates when the mice were supple-
mented with water containing 1.3% choline chloride (sup-
plementary Fig. 1). 
 We introduced the FMO3 transgene on to a hyperlipid-
emic mouse model, the E3L Tg mouse ( 11 ) for further 
analysis. The E3L Tg was chosen because it shows a domi-
nant effect with respect to hypercholesterolemia, in con-
trast to the LDLRKO model, and thus reduces the breeding 
required for generation of the FMO3 Tg mice on a hyper-
lipidemic background. When fed either low-fat chow or 
HF/HC diets, the FMO3 Tg/E3L Tg mice exhibited sig-
nifi cantly increased plasma TG, VLDL/IDL/LDL, and un-
esterifi ed cholesterol as compared with the E3L Tg mice 
( Table  3 ), consistent with the ASO experiments, which 
had the opposite effects.  We also observed increased glu-
cose and insulin levels in the FMO3 Tg mice ( Table 3 ; P   
0.1). No signifi cant changes in HDL cholesterol or free 
fatty acid levels were observed between these two groups of 
mice fed the same diet ( Table 3 ). FPLC analysis of plasma 
lipoproteins revealed increased levels of TG, TC, and 
phosphatidylcholine in the VLDL fractions of the FMO3 
Tg plasma samples as compared with those of the E3L Tg 
samples (supplementary Fig. 2A–C) from mice fed the 
HF/HC diet. Increased levels of TC and phosphatidylcho-
line were also observed in the IDL/LDL fractions of the 
FMO3 Tg plasma samples (supplementary Fig. 2B, C). No 
changes in TC or phosphatidylcholine levels were ob-
served between the HDL fractions of the two groups (sup-
plementary Fig. 2B, C). 
 When fed an HF/HC diet, the FMO3 Tg/E3L Tg mice 
exhibited a 40% increase in liver FMO activity ( P = 0.08) as 
compared with the E3L Tg mice ( Fig. 8A , left panel). 
 There was a trend of increased circulating TMAO levels 
( P = 0.09) in the FMO3 Tg/E3L Tg mice as compared with 
the E3L Tg mice ( Fig. 8A , right panel), whereas circulating 
 TABLE 3. Plasma lipid, lipoprotein, glucose, and insulin levels of FMO3 Tg/E3L Tg and E3L Tg mice maintained on chow or HF/HC diets 









E3L Tg Chow 8 104 (13) 93 (9) 48 (10) 45 (5) 29 (3) 36 (2) 182 (13) 852 (172)
FMO3 Tg/E3L Tg Chow 12 148 (8) a 115 (6) a 51 (4) 64 (5) a 37 (2) a 38 (2) 205 (4) b 1,454 (222) b 
E3L Tg HF/HC 9 438 (71) 702 (92) 87 (3) 616 (94) 243 (43) 44 (2) 139 (15) 912 (240)
FMO3 Tg/E3L Tg HF/HC 13 619 (53) a 916 (44) a 95 (4) 821 (44) a 335 (19) a 37 (3) 164 (7) b 981 (65) c 
Mice fed the chow diet were fasted for 4 h. Mice fed the HF/HC diet were fasted for 16 h. Values shown are means (standard errors) of the 
groups. Units are mg/dl except insulin, for which the unit is pg/ml. 
 a P   0.05 versus E3L Tg of the same diet.
 b P < 0.1 versus E3L Tg of the same diet. 
 c Natural log-transformed data were used for comparison;  P = 0.1 versus E3L Tg of the same diet.
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lipogenesis we observed in Ad-FMO3-infected cells 
( Fig. 9C ) might have been caused by increased availability 
of glucose in these cells, leading to elevated acetyl-CoA, 
the precursor for fatty acid synthesis. 
 Associations between plasma TMAO levels, lipid levels, 
and atherosclerosis resulting from natural variation 
among inbred strains of mice 
 Our FMO3 knockdown and overexpression studies sug-
gest a role for FMO3 in modulating plasma lipoprotein 
levels in mice. We have, therefore, explored whether com-
mon functional variations of FMO3 in mice might also 
infl uence plasma lipid traits. We previously reported a 
signifi cant  cis -expression quantitative trait locus ( P = 1.78 × 
10   6 ) located in the  Fmo3 gene (SNP rs30760034, located 
in Chr. 1, 164896447 bp) that controls the hepatic FMO3 
mRNA levels among a panel of   100 different inbred 
strains of mice ( 30 ). Indeed, in this same panel, signifi cant 
associations were observed between plasma lipid traits (in-
cluding VLDL/IDL/LDL-cholesterol, total, HDL-cholesterol, 
and unesterifi ed cholesterol) and SNPs located in a re-
gion of mouse chromosome 1 within 1 Mb of the  Fmo3 locus 
(supplementary Table 5). 
 Furthermore, we previously observed that atheroscle-
rotic lesion size was signifi cantly correlated with both 
plasma lipid and TMAO levels among 22 inbred strains of 
apoB Tg/HMDP mice ( 1, 23 ). We performed biweight 
Ad-CMV-infected cells ( Fig. 9A , left panel).  The FMO ac-
tivity was increased by 14-fold in the Ad-FMO3-infected 
cells as well ( Fig. 9A , right panel). The glucose secretion 
rate of the Ad-FMO3-infected cells was increased by   80% 
as compared with that of the Ad-CMV-infected cells 
( Fig. 9B ) when the cells were incubated with a glucose-
free media that promotes gluconeogenesis. In addition, 
the Ad-FMO3-infected cells exhibited a 43% increase in 
lipogenesis as determined by incorporation of  14 C-acetate 
into cellular lipids including free fatty acid, phospholipid, 
TG, cholesterol, and cholesteryl ester, as compared with 
the Ad-CMV-infected cells ( Fig. 9C ). Interestingly, the 
mRNA levels of genes involved in gluconeogenesis, such as 
ALT, G6PC, and PEPCK, were signifi cantly elevated in the 
Ad-FMO3-infected cells ( Fig. 9D ). The expression of OTC, 
a gene involved in the urea cycle, was also signifi cantly in-
creased in the Ad-FMO3-infected cells as compared with 
the Ad-CMV-infected cells ( Fig. 9D ). Our data suggest that 
FMO3 overexpression is associated with increased expres-
sion of genes involved in gluconeogenesis. The mRNA lev-
els of several genes involved in lipogenesis, including 
SREBP - 1c, a transcription factor that controls the expres-
sion of lipogenesis genes, FASN, and stearoyl-CoA desat-
urase (SCD), were similar between the Ad-FMO3- and 
Ad-CMV-infected cells (data not shown). Therefore, FMO3 
overexpression in cell culture did not directly increase the 
expression of genes involved in lipogenesis. The increased 
 Fig.  8. FMO3 overexpression in Tg mice infl u-
ences liver FMO activity, plasma TMAO, hepatic 
lipid content, bile acid pool size and composition, 
body weight, adiposity, and atherosclerotic lesion 
size. FMO3 Tg/E3L Tg and E3L Tg mice were fed 
the HF/HC diet for 16 weeks prior to tissue collec-
tion. Liver FMO activity (n = 7 for each group) and 
plasma TMA and TMAO levels (n = 8 to 11 for each 
group) (A); hepatic levels (n = 10 for each group) of 
TG, TC, and phosphatidylcholine (PC) (B); and 
bile acid (BA) pool size and composition (n = 7 to 
10 for each group) (C) were measured. For bile acid 
composition, only the major (  0.5% of total 
amount) bile acid species are plotted. Body weight 
(D) and percent weight (E) of four fat pads (go-
nadal, retroperitoneal, subcutaneous, and mesen-
tery fat pads), normalized by the body weight, were 
determined (n = 9 to 12 for each group). F: Mean 
atherosclerotic lesion sizes at the aortic root region 
were quantifi ed (n = 15 for E3L Tg, n = 31 for FMO3 
Tg/E3L Tg). The lesion data were logarithmically 
transformed for the  t -test. Student’s  t -test: *  P < 0.05 
as compared with the E3L Tg mice. 
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IDL/LDL-cholesterol (supplementary Table 6A), with the 
order of association: VLDL/IDL/LDL cholesterol > HDL 
cholesterol > TMAO. To estimate the relative importance 
of these factors in atherosclerosis development in mice, we 
performed stepwise linear regression analysis (supplemen-
tary Table 6B). The analysis showed that among these 
three factors, VLDL/IDL/LDL-cholesterol was the most 
important predictor of lesion size, followed by HDL-
cholesterol and then TMAO (supplementary Table 6B). 
 We conclude that common natural variations perturb-
ing expression of FMO3 in mice infl uence plasma lipid 
levels as well as TMA/TMAO levels. 
 DISCUSSION 
 We began this study to test whether inhibition of FMO3 
would reduce atherosclerosis in hyperlipidemic mouse 
models, providing a possible approach to human therapy 
for the disease. We were surprised to discover that pertur-
bation of FMO3 expression has profound effects on lipid 
and glucose metabolism, as well as potential proinfl amma-
tory effects. Hepatic gene expression analysis revealed 
signifi cantly decreased expression of genes involved in 
gluconeogenesis and lipogenesis in the FMO3 ASO-treated 
mice as compared with the control mice, providing a mo-
lecular basis for the lower lipid and glucose levels seen in 
these mice. These results reveal a novel role of FMO3, and 
possibly TMA/TMAO, in lipid and glucose metabolism. 
Clearly, efforts to modulate TMAO levels for therapeutic 
purposes by targeting FMO3 will have to consider these 
metabolic effects. 
 We observed that FMO3-specifi c ASO knockdown in 
LDLRKO mice led to 90% decreases in hepatic FMO3 pro-
tein and FMO3 activity levels and resulted in signifi cant 
decreases in plasma levels of TMAO and atherosclerosis. 
In addition, we observed decreased levels of plasma lipids, 
glucose, insulin, and ketone bodies, as well as concomitant 
increases in plasma levels of glucogenic and ketogenic 
amino acids, suggesting decreased hepatic gluconeogene-
sis and ketogenesis. Hepatic glucose and lipid levels were 
also signifi cantly decreased in the FMO3 ASO-treated 
mice. Treatment of female and male B6 mice by two inde-
pendent FMO3-specifi c ASOs led to similar decreases in 
plasma lipids, glucose, and insulin levels, suggesting that 
the observed metabolic changes associated with the FMO3 
ASO treatment were caused by FMO3 defi ciency rather 
than a nonspecifi c effect. Using a complementary ap-
proach, we found that FMO3 overexpression in Tg mice 
led to moderate but signifi cant increases in liver FMO ac-
tivity and signifi cant increases in plasma lipid levels, he-
patic TG content, and adiposity. There was a trend of 
increased plasma glucose and insulin levels and increased 
atherosclerosis in FMO3 Tg mice as well. 
 The lipid and glucose changes observed in our studies 
in response to perturbations of FMO3 are not likely to be 
mediated by TMAO because elevated TMAO levels caused 
by dietary supplementation of TMAO,  L -carnitine, or 
choline did not lead to signifi cant changes in plasma TG, 
midcorrelation analyses of these data to examine the pair-
wise relationships between plasma TMAO, HDL-cholesterol, 
and VLDL/IDL/LDL-cholesterol levels, as well as athero-
sclerotic lesion size among the 22 strains of apoB Tg/
HMDP mice (133 female mice) (supplementary Table 
6A). We observed a moderate but signifi cant positive cor-
relation between TMAO and VLDL/IDL/LDL levels and 
an inverse correlation between TMAO and HDL levels 
(supplementary Table 6A). The positive association be-
tween TMAO and VLDL/IDL/LDL levels is consistent 
with our results because FMO3 knockdown led to de-
creases in both TMAO and VLDL/IDL/LDL-cholesterol 
levels, whereas FMO3 overexpression increased both. The 
inverse correlation between TMAO and HDL-cholesterol 
levels suggests that there are additional factors, other 
than FMO3, that have effects on HDL-cholesterol levels 
in the set of mouse strains. Moreover, we observed signifi -
cant associations between atherosclerotic lesion size and 
plasma levels of TMAO, HDL-cholesterol, and VLDL/
 Fig.  9. FMO3 overexpression in Hep3B cells leads to increased 
glucose production and lipogenesis. Hep3B cells were infected 
with Ad-CMV or Ad-FMO3 for 2 days, and FMO3 protein levels 
(n = 4 for each group, left panel) and FMO activity (n = 3 for each 
group, right panel) (A), glucose secretion rates (B), lipogenesis 
rates (C), and mRNA levels (D) were measured. For B–D, n = 4 
to 6 for each group. Student’s  t -test: *  P < 0.05, **  P < 0.01, and *** 
 P < 0.0001 as compared with the Ad-CMV group, respectively. 
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genes involved in bile acid synthesis, including  Cyp7a1 and 
 Cyp8b1 ( 21, 41 ), and plays a role in modulating infl amma-
tory responses in the artery wall and liver by interference 
with the nuclear factor  	 B (NF- 	 B) pathway through di-
rect binding to p65 ( 42 ) and other mechanisms ( 43, 44 ). 
 The microarray data also revealed decreased expression 
of  Klf15 and some of its target genes in the livers of FMO3 
ASO-treated mice. Recent studies have shown the impor-
tance of KLF15 in modulating gluconeogenesis, amino 
acid degradation, and urea cycle ( 26–28 ). Moreover, 
KLF15 regulates infl ammation by altering the acetylation 
status and activity of NF- 	 B through direct interaction with 
p300 ( 45 ). Thus, the increased hepatic infl ammation we 
observed in the FMO3 ASO-treated mice might have been 
caused by impaired PPAR  and KLF15 activities. 
 Previously, dietary TMAO supplementation was shown 
to decrease bile acid pool size in ApoEKO mice ( 2 ). In 
contrast, we observed decreased TMAO levels and de-
creased bile acid pool sizes in FMO3 ASO-treated LD-
LRKO mice. Furthermore, FMO3 overexpression led to 
increased bile acid pool size ( Fig. 8C ) in the FMO3 Tg 
mice. These results suggest that FMO3 infl uences bile acid 
homeostasis through pathways other than TMAO. The ob-
served changes in bile acid metabolism could be linked to 
the infl ammatory effects in liver. Specifi cally, TNF  has 
been previously demonstrated to decrease the expression 
of  Cyp7a1 through activation of the MAPK pathway ( 46 ). 
Moreover, decreased Cyp7a1 and Cyp8b1 expression due 
to reduced transactivation by PPAR  in the livers of FMO3 
ASO-treated mice probably contributed to the decreased 
bile acid pool size as well. 
 Our study suggests a role for FMO3 in modulating adi-
posity as well because FMO3 knockdown and overexpres-
sion lead to signifi cantly decreased and increased adiposity, 
respectively. This could be modulated in part by the ef-
fects of FMO3 on plasma TG and glucose levels. Thus, 
lower plasma TG and glucose levels in the FMO3 ASO-
treated LDLRKO mice lead to lower TG accumulation and 
decreased fat pad weight/adiposity, whereas the opposite 
is true in the FMO3 Tg mice. 
 Our results in mice suggest that naturally occurring sub-
tle variations in FMO3 expression can signifi cantly perturb 
lipid metabolism as well as TMA/TMAO levels. Thus, we 
observed that among different inbred strains of mice, 
plasma lipid levels mapped to the region of the  Fmo3 gene 
and that TMAO levels were signifi cantly correlated with 
plasma lipid levels. This raises the possibility that common 
variations of the FMO3 gene in human populations may 
also affect lipid or glucose metabolism and that these could 
explain, in part, the observed correlations between TMAO 
level and atherosclerosis. This does not appear to be the 
case, however, because plasma lipids were not correlated 
with TMAO in human studies, and neither TMAO levels 
nor lipid levels were associated with the  FMO3 gene in 
a genome-wide association study ( 9 ). Perhaps common 
variations in FMO3 expression or activity do not occur 
in the human populations that were studied. Alternatively, 
there may be differences between mice and humans in 
the metabolic interactions of FMO3. The recessive disorder 
cholesterol, lipoprotein, or glucose levels, or hepatic TG 
or cholesterol levels in apoE null (ApoEKO) mice ( 2, 3 ). 
On the other hand, in a study using male C57BL/6J mice, 
TMAO supplementation was associated with signifi cantly 
decreased plasma TG and TC levels, the opposite of our 
fi ndings, and increased insulin levels ( 31 ). Moreover, 
overexpression of FMO3 in Hep3B cells by adenovirus-
mediated gene transduction led to signifi cantly increased 
glucose production and lipogenesis, suggesting a direct 
role for FMO3 in modulating lipid and glucose homeosta-
sis. While TMA/TMAO may explain some of the effects on 
lipids and glucose metabolism, we feel the data are most 
consistent with the concept that FMO3 modulates the he-
patic level(s) of an unknown physiological substrate(s), 
which, in turn, infl uences lipid and glucose metabolism in 
the liver. 
 The decreased lipogenesis we observed in the livers of 
FMO3 ASO-treated mice could be the result of decreased 
insulin levels. Insulin regulates liver lipogenesis through a 
series of signaling steps that activate SREBP-1c ( 32–37 ), 
which in turn increases the expression of lipogenic genes 
such as  Fasn and  Scd-1 . We observed decreased hepatic ex-
pression of SREBP-1c and lipogenesis genes in the FMO3 
ASO-treated mice, consistent with decreased insulin 
levels. 
 Our data revealed decreased hepatic gluconeogenesis 
in the FMO3 ASO-treated mice. Hepatic gluconeogenesis 
is closely regulated by the opposing actions of insulin and 
glucagon. In a fed state, insulin inhibits gluconeogenesis 
through AKT (also known as protein kinase B)-mediated 
phosphorylation of the transcription factor FOXO1, lead-
ing to its nuclear exclusion and degradation ( 38 ). In the 
fasting state, glucagon stimulates gluconeogenesis by mul-
tiple pathways, leading to increased expression of FOXO1, 
G6PC, and PEPCK ( 39, 40 ). We observed decreased levels 
of FOXO1 in the FMO3 ASO-treated mice. However, we 
did not observe signifi cant differences in circulating gluca-
gon levels between the FMO3 ASO-treated and the control 
mice. 
 In an attempt to understand the mechanism by which 
FMO3 expression is linked to lipid and glucose metabo-
lism, we carried out global microarray expression analyses. 
The studies revealed that FMO3 knockdown is associated 
with a preferentially decreased expression of PPAR  and 
its target genes in the liver, possibly due to reduced he-
patic concentrations of PPAR  ligands, including palmi-
toleate, oleate,   - or   -linolenate, and EPA ( Fig. 7D ). Both 
linolenate and EPA are essential fatty acids derived en-
tirely from dietary sources. Because there was no differ-
ence in the daily fecal TG output between the mice treated 
with FMO3 or control ASO ( Fig. 6D ), it is unlikely that 
FMO3 knockdown impaired the intestinal absorption of 
essential fatty acids. However, FMO3 may modulate the ca-
tabolism of these unsaturated fatty acids and indirectly in-
fl uence the activation of PPAR  . PPAR  is activated during 
fasting and stimulates fatty acid oxidation, ketogenesis, 
and gluconeogenesis through transactivation of its target 
genes ( 21 ) and thus could explain many of the observed 
effects of the FMO3 perturbation. PPAR  also regulates 
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trimethylaminuria, due to loss of function mutations of 
 FMO3 gene, occurs at a frequency of   1 in 10,000 in Cauca-
sian populations ( 4 ). It will be of interest to examine 
whether these individuals or obligate heterozygous individ-
uals exhibit alterations in lipid and glucose metabolism. 
 In summary, we uncovered a novel role for FMO3 in 
modulating glucose and lipid homeostasis in vivo. Our 
fi ndings suggest that FMO3 modulates lipid and glucose 
in a dose-dependent manner and that these effects are 
most likely independent of TMA/TMAO metabolism. 
Whether the underlying mechanism involves unknown 
catalytic activities of FMO3 or regulatory functions distinct 
from its catalytic activity is unknown. However, our data 
revealed that FMO3 infl uences the activities of two master 
regulators of hepatic metabolite homeostasis and infl am-
mation, namely PPAR  and KLF15.  
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